WAVE Life Sciences Equity 2024

WAVE Life Sciences Aktienanalyse

What does WAVE Life Sciences do?

WAVE Life Sciences Ltd is a biotechnology company dedicated to the development of nucleic acid preparations for the treatment of genetically inherited diseases. The company was founded in 2012 and is headquartered in Singapore. WAVE Life Sciences' business model is focused on developing specific nucleic acid sequences that can selectively silence or correct defective genes associated with various diseases. The company offers these sequences as therapeutics that enable personalized treatment for patients. The company utilizes a proprietary platform technology called "AVIENNA" to selectively silence or correct defective genes. "AVIENNA" aims to optimize the physical properties of nucleic acids to improve their effectiveness and duration of action. WAVE Life Sciences has three business areas: neurology, cardiovascular diseases, and metabolic diseases. In the neurology area, the company focuses on the development of therapeutics for the treatment of amyotrophic lateral sclerosis (ALS) and Huntington's disease. In the cardiovascular diseases area, the company is working on therapeutics for cardiovascular diseases such as heart attack, stroke, and atherosclerosis. In the metabolic diseases area, WAVE Life Sciences is focused on the development of therapeutics for rare metabolic diseases such as Crohn's disease and Pompe disease. The most well-known product in WAVE Life Sciences' pipeline is "WVE-120101", a therapeutic for the treatment of ALS. The drug has been developed to target mutations in the SOD1 gene that can lead to ALS. WVE-120101 is currently in clinical trials and has the potential to become the first approved medication for patients with ALS. WAVE Life Sciences also collaborates closely with other companies to exchange technologies and know-how. In 2018, the company entered into a strategic partnership with Takeda Pharmaceutical to jointly develop therapeutics for the treatment of gastrointestinal diseases. The partnership aims to leverage the strengths of both companies and accelerate the development of innovative therapeutics. Overall, WAVE Life Sciences has a promising portfolio of therapeutics that have the potential to improve the lives of patients with genetically inherited diseases. The company follows a systematic and scientifically-based strategy in drug development to ensure the effectiveness and safety of its products. With its innovative business model and dedicated research and development, WAVE Life Sciences is well positioned to achieve a leading position in the biotechnology industry in the future. WAVE Life Sciences ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing WAVE Life Sciences's Equity

WAVE Life Sciences's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding WAVE Life Sciences's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating WAVE Life Sciences's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

WAVE Life Sciences's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in WAVE Life Sciences’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about WAVE Life Sciences stock

What is the equity of WAVE Life Sciences this year?

WAVE Life Sciences has equity of 47.5 M USD this year.

What was the equity of WAVE Life Sciences compared to the previous year?

The equity of WAVE Life Sciences has increased/decreased by -227.7% decreased compared to the previous year.

What impact does a high equity have on investors of WAVE Life Sciences?

A high equity is advantageous for investors of WAVE Life Sciences as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of WAVE Life Sciences?

A low equity can be a risk for investors of WAVE Life Sciences, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of WAVE Life Sciences affect the company?

An increase in equity of WAVE Life Sciences can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of WAVE Life Sciences affect the company?

A reduction in equity of WAVE Life Sciences can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of WAVE Life Sciences?

Some factors that can affect the equity of WAVE Life Sciences include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of WAVE Life Sciences so important for investors?

The equity of WAVE Life Sciences is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can WAVE Life Sciences take to change the equity?

To change equity, WAVE Life Sciences can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does WAVE Life Sciences pay?

Over the past 12 months, WAVE Life Sciences paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, WAVE Life Sciences is expected to pay a dividend of 0 USD.

What is the dividend yield of WAVE Life Sciences?

The current dividend yield of WAVE Life Sciences is .

When does WAVE Life Sciences pay dividends?

WAVE Life Sciences pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of WAVE Life Sciences?

WAVE Life Sciences paid dividends every year for the past 0 years.

What is the dividend of WAVE Life Sciences?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is WAVE Life Sciences located?

WAVE Life Sciences is assigned to the 'Health' sector.

Wann musste ich die Aktien von WAVE Life Sciences kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of WAVE Life Sciences from 11/5/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/5/2024.

When did WAVE Life Sciences pay the last dividend?

The last dividend was paid out on 11/5/2024.

What was the dividend of WAVE Life Sciences in the year 2023?

In the year 2023, WAVE Life Sciences distributed 0 USD as dividends.

In which currency does WAVE Life Sciences pay out the dividend?

The dividends of WAVE Life Sciences are distributed in USD.